Track your holdings and dividends manually for free. Subscribe to link your brokerage through Plaid and automatically sync holdings and dividend payments.
Data last updated: Nov 16, 2026
Snapshot (as of Nov 16, 2026): Bristol-Myers Squibb Company (BMY) pays a $2.52 annual dividend ($0.63 quarterly), yielding 3.97% at $63.17/share. Next ex-dividend date 2026-10-02. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.97%
Annual Dividend: $2.52 per share
Payout Ratio: 55.9%
Ex-Dividend Date: 2026-10-02
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Bristol-Myers Squibb Company dividend investors are looking at a pharmaceutical giant with a portfolio spanning oncology, cardiovascular, and immunology treatments, including blockbusters like Eliquis and Opdivo. The current yield sits at 4.01%, placing BMY in high-yield territory for a large healthcare company. Quarterly payments of $0.63 per share add up to a trailing annual rate of $2.52, with the next ex-dividend date set for October 2, 2026. A beta of 0.186 signals very low price volatility, which suits income-focused investors who prioritize payment predictability over share price swings.
Bristol-Myers Squibb Company pays out 55.9% of earnings as dividends, a payout ratio classified as moderate (40–60%). That level leaves a meaningful buffer, and the company's portfolio of treatments for serious conditions, including multiple myeloma drugs like Revlimid and Pomalyst and the stroke-prevention drug Eliquis, supports recurring demand for its products. Bristol-Myers Squibb Company dividend safety faces its most visible pressure from patent expirations on key drugs, a structural risk for any large pharmaceutical company, though the data block does not quantify that exposure directly. The payout ratio itself does not signal immediate stress.
Bristol-Myers Squibb Company dividend history shows a CAGR of 4.3% per year from 2006 to 2025. Per-share payments grew from $1.12 to $2.48 over that period (2026 is a partial year and excluded from the CAGR calculation). The largest annual increase in the window was 39.6% in 2020, a spike that stands out sharply against the otherwise modest pace. Growth is slow in most years, and the history table includes at least one year-over-year decline exceeding 5%, so the path has not been linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +4.7% | $2.16 (2022) | $2.48 (2025) |
| 5-Year | +1.6% | $2.29 (2020) | $2.48 (2025) |
| 10-Year | +5.2% | $1.49 (2015) | $2.48 (2025) |
BMY fits income-focused investors who want a high-yield pharmaceutical holding with low share price volatility. The yield of 4.01%, classified as high (above 4%), sits above the stock's own 5-year average of 3.86%, meaning the current entry point offers slightly more income than the historical norm. Four consecutive years of dividend increases show recent discipline, though the long-term growth rate of 4.3% per year is modest. The trade-off is straightforward: Bristol-Myers Squibb Company stock delivers above-average income and very low beta, but dividend growth is slow and the history includes past declines, so total return upside is limited.
| Payment Date | Amount per Share |
|---|---|
| 2026-10-02 | $0.6300 |
| 2026-07-02 | $0.6300 |
| 2026-04-02 | $0.6300 |
| 2026-01-02 | $0.6300 |
| 2025-10-03 | $0.6200 |
| 2025-07-03 | $0.6200 |
| 2025-04-04 | $0.6200 |
| 2025-01-03 | $0.6200 |
| 2024-10-04 | $0.6000 |
| 2024-07-05 | $0.6000 |
| Year | Total Dividends |
|---|---|
| 2026 | $2.5200 |
| 2025 | $2.4800 |
| 2024 | $2.4000 |
| 2023 | $2.2800 |
| 2022 | $2.1600 |
Project income from BMY with the BMY dividend calculator or track your full portfolio with the dividend tracker.